Is there a link between carbamylation and citrullination in periodontal disease and rheumatoid arthritis?

Medical Hypotheses

Volumn 84, Issue 6, 2015, Pages 570-576

  Bright, R ^a   Proudman, S M ^a,b   Rosenstein, E D ^c   Bartold, P M ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c Overlook Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ENOLASE; ARGININE; CITRULLINATED PROTEIN ANTIBODY; CITRULLINE; COLLAGEN TYPE 2; FIBRINOGEN; LYSINE; PROTEIN ANTIBODY; PROTEIN ARGININE DEIMINASE; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; VIMENTIN; AUTOANTIBODY; CARBAMIC ACID DERIVATIVE;

AMINO ACID ANALYSIS; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; CARBAMOYLATION; CITRULLINATION; GINGIVITIS; HUMAN; NONHUMAN; PATHOGENESIS; PERIODONTAL DISEASE; PERIODONTITIS; PREDICTIVE VALUE; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN MODIFICATION; PROTEIN PROCESSING; RHEUMATOID ARTHRITIS; BIOLOGICAL MODEL; BLOOD; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CARBAMATES; CITRULLINE; HUMANS; MODELS, BIOLOGICAL; PERIODONTAL DISEASES; RHEUMATOID FACTOR;

EID: 84933676500     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2015.03.006     Document Type: Article

References (71)

1. Bartold P.M., Van Dyke T.E. Periodontitis: a host-mediated disruption of microbial homeostasis. Unlearning learned concepts. Periodontol 2000 2013, 62:203-217.
2. Linden G.J., Lyons A., Scannapieco F.A. Periodontal systemic associations: review of the evidence. J Periodontol 2013, (4 Suppl.):S8-S19.
3. Page R.C., Offenbacher S., Schroeder H.E., Seymour G.J., Kornman K.S. Advances in the pathogenesis of periodontitis: summary of developments, clinical implications and future directions. Periodontol 2000 1997, 14:216-428.
4. Eke P.I., Dye B.A., Wei L., Thornton-Evans G.O., Genco R.J. Prevalence of periodontitis in adults in the United States: 2009 and 2010. J Dent Res 2012, 91:914-920.
5. Albandar J.M., Tinoco E.M. Global epidemiology of periodontal diseases in children and young persons. Periodontol 2002, 29:153-176.
6. Christodoulou C., Choy E.H. Joint inflammation and cytokine inhibition in rheumatoid arthritis. Clin Exp Med 2006, 6:13-19.
7. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003, 423:356-361.
8. Looper K.J., Mustafa S.S., Zelkowitz P., Purden M., Baron M. Work instability and financial loss in early inflammatory arthritis. Int J Rheum Dis 2012, 15:546-553.
9. Snyderman R, McCarty GA. Analogous mechanisms of tissue destruction in rheumatoid arthritis and periodontal disease. In: Genco RJ, Mergenhagen SE, editors. Host-parasite interaction in periodontal diseases. Washington (DC); 1982.
10. Bartold P.M., Mariotti A.J. Association between periodontitis and rheumatoid arthritis. Chapter 13. Periodontal disease and overall health: a clinician's guide 2011, Professional Audience Communications Inc.
11. Bartold P.M., Marshall R.I., Haynes D.R. Periodontitis and rheumatoid arthritis: a review. J Periodontol 2005, 76(11 Suppl.):2066-2074.
12. de Pablo P., Chapple I.L., Buckley C.D., Dietrich T. Periodontitis in systemic rheumatic diseases. Nat Rev Rheumatol 2009, 5:218-224.
13. Kaur S., White S., Bartold P.M. Periodontal disease and rheumatoid arthritis: a systematic review. J Dent Res 2013, 92:399-408.
14. Kaur S., Bright R., Bartold P.M. Does periodontal treatment influence clinical and biochemical measures for rheumatoid arthritis? A systematic review and meta-analysis. Semin Arthritis Rheum 2014 Apr 28, [Epub ahead of print].
15. Ollier W.E., Harrison B., Symmons D. What is the natural history of rheumatoid arthritis?. Best Pract Res Clin Rheumatol 2001, 15:27-48.
16. Haytac M.C., Ozcelik O., Mariotti A. Periodontal disease in men. Periodontol 2000 2013, 61:252-265.
17. Aceves-Avila F.J., Medina F., Fraga A. The antiquity of rheumatoid arthritis: a reappraisal. J Rheumatol 2001, 28:751-757.
18. Clarke N.G., Carey S.E., Srikandi W., Hirsch R.S., Leppard P.I. Periodontal disease in ancient populations. Am J Phys Anthropol 1986, 71:173-183.
19. Nair S., Faizuddin M., Dharmapalan J. Role of autoimmune responses in periodontal disease. Autoimmune Dis 2014, 2014:596824. Epub 2014. 10.1155/2014/596824.
20. Demoruelle M.K., Deane K.D., Holers V.M. When and where does inflammation begin in rheumatoid arthritis. Curr Opin Rheumatol 2014, 26:64-71.
21. Holers V.M. Autoimmunity to citrullinated proteins and the initiation of rheumatoid arthritis. Curr Opin Rheumatol 2013, 25:726-735.
22. Vossenaar E.R., Zendman A.J., van Venrooij W.J., Pruijn G.J. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 2003, 25:1106-1118.
23. Shi J., Knevel R., Suwannalai P., et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A 2011, 108:17372-17377.
24. Speer T., Owala F.O., Holy E.W., et al. Carbamylated low-density lipoprotein induces endothelial dysfunction. Eur Heart J 2014 Mar 21, [Epub ahead of print].
25. Wegner N., Lundberg K., Kinloch A., et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev 2010, 233:34-54.
26. Bicker K.L., Thompson P.R. The protein arginine deiminases: structure, function, inhibition, and disease. Biopolymers 2013, 99:155-163.
27. Vossenaar E.R., Radstake T.R., van der H.A., van Mansum M.A., Dieteren C., de Rooij D.J. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis 2004, 63:281-373.
28. Foulquier C., Sebbag M., Clavel C., et al. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum 2007, 56:3541-3553.
29. Masson-Bessière C., Sebbag M., Girbal-Neuhauser E., et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 2001, 166:4177-4184.
30. El-Gabalawy H. The preclinical stages of RA: lessons from human studies and animal models. Best Pract Res Clin Rheumatol 2009, 23:49-58.
31. Kroot E.J., de Jong B.A., van Leeuwen M.A., et al. Prognostic value of anti-cyclic citrullinated peptide antibody in recent-onset rheumatoid arthritis. Arthritis Rheum 2000, 43:1831-1835.
32. Rantapää-Dahlqvist S., de Jong B.A., et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48:2741-2749.
33. Smit M.D., Westra J., Vissink A., Doornbos-van der Meer B., Brouwer E., van Winkelhoff A.J. Periodontitis in established rheumatoid arthritis patients: a cross-sectional clinical, microbiological and serological study. Arthritis Res Ther 2012, 14:R222.
34. Rosenstein E.D., Greenwald, Kushner L.J., Weissmann G. Hypothesis: the humoral immune response to oral bacteria provides a stimulus for the development of rheumatoid arthritis. Inflammation 2004, 28:311-318.
35. Wegner N., Wait R., Sroka A., et al. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and alpha-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum 2010, 62:2662-2672.
36. McGraw W.T., Potempa J., Farley D., Travis J. Purification, characterization, and sequence analysis of a potential virulence factor from Porphyromonas gingivalis, peptidylarginine deiminase. Infect Immun 1999, 67:3248-3256.
37. Harvey G.P., Fitzsimmons T.R., Dhamarpatni A.A., Marchant C., Haynes D.R., Bartold P.M. Expression of peptidylarginine deiminase-2 and -4, citrullinated proteins and anti-citrullinated protein antibodies in human gingiva. J Periodontal Res 2013, 48:252-261.
38. Nesse W., Westra J., van der Wal J.E., Abbas F., Nicholas A.P., Vissink A., et al. The periodontium of periodontitis patients contains citrullinated proteins which may play a role in ACPA (anti-citrullinated protein antibody) formation. J Clin Periodontol 2012, 39:599-607.
39. Lundberg K., Kinloch A., Fisher B.A., et al. Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 2008, 58:3009-3019.
40. Burska A.N., Hunt L., Boissinot M., Strollo R., Ryan B.J., Vital E., et al. Autoantibodies to posttranslational modifications in rheumatoid arthritis. Mediators Inflamm 2014, 2014:492873.
41. Erill S., Calvo R., Carlos R. Plasma protein carbamylation and decreased acidic drug protein binding in uremia. Clin Pharmacol Ther 1980, 27:612-618.
42. Fluckiger R., Harmon W., Meier W., Loo S., Gabbay K.H. Hemoglobin carbamylation in uremia. N Engl J Med 1981, 304:823-827.
43. Pietrement C., Gorisse L., Jaisson S., Gillery P. Chronic increase of urea leads to carbamylated proteins accumulation in tissues in a mouse model of CKD. PLoS One 2013, 8:e82506.
44. Shi J., van Veelen P.A., Mahler M., et al. Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev 2014, 13:225-230.
45. Wang Y., Li M., Stadler S., et al. Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J Cell Biol 2009, 184:205-213.
46. Brinkmann V., Reichard U., Goosmann C., Fauler B., Uhlemann Y., Weiss D.S., et al. Neutrophil extracellular traps kill bacteria. Science 2004, 303:1532-1535.
47. Parker H., Albrett A.M., Kettle A.J., Winterbourn C.C. Myeloperoxidase associated with neutrophil extracellular traps is active and mediates bacterial killing in the presence of hydrogen peroxide. J Leukoc Biol 2012, 91:369-376.
48. Wang Z., Nicholls S.J., Rodriguez E.R., et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007, 13:1176-1184.
49. Sirpal S. Myeloperoxidase-mediated lipoprotein carbamylation as a mechanistic pathway for atherosclerotic vascular disease. Clin Sci 2009, 116:681-695.
50. Jaisson S., Pietrement C., Gillery P. Carbamylation-derived products: bioactive compounds and potential biomarkers in chronic renal failure and atherosclerosis. Clin Chem 2011, 57:1499-1505.
51. Trouw L.A., Mahler M. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun Rev 2012, 12:318-322.
52. Shi J., van de Stadt L.A., Levarht E.W., et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis 2014, 73:780-783.
53. Kummu O., Turunen S.P., Prus P., Lehtimäki J., Veneskoski M., Wang C., et al. Human monoclonal Fab and human plasma antibodies to carbamyl-epitopes cross-react with malondialdehyde-adducts. Immunology 2014, 141:416-430.
54. Klareskog L., Amara K., Malmstrom V. Adaptive immunity in rheumatoid arthritis: anticitrulline and other antibodies in the pathogenesis of rheumatoid arthritis. Curr Opin Rheumatol 2014, 26:72-79.
55. Mydel P., Wang Z., Brisslert M., Hellvard A., Dahlberg L.E., Hazen S.L., et al. Carbamylation-dependent activation of T cells: a novel mechanism in the pathogenesis of autoimmune arthritis. J Immunol 2010, 184:6882-6890.
56. Scinocca M., Bell D.A., Racape M., et al. Antihomocitrullinated fibrinogen antibodies are specific to rheumatoid arthritis and frequently bind citrullinated proteins/peptides. J Rheumatol 2014, 41:270-279.
57. Willemze A., Toes R.E., Huizinga T.W., Trouw L.A. New biomarkers in rheumatoid arthritis. Neth J Med 2012, 70:392-399.
58. van Schaardenburg D. Gauging rheumatoid arthritis. Neth J Med 2012, 70:389-391.
59. Jiang X., Trouw L.A., van Wesemael T.J., Shi J., Bengtsson C., Källberg H., et al. Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Ann Rheum Dis 2014, 73:1761-1768.
60. Freire M.O., Van Dyke T.E. Natural resolution of inflammation. Periodontol 2000 2013, 63:149-164.
61. Vitkov L., Klappacher M., Hannig M., Krautgartner W.D. Extracellular neutrophil traps in periodontitis. J Periodontal Res 2009, 44:664-672.
62. Cooper P.R., Palmer L.J., Chapple I.L. Neutrophil extracellular traps as a new paradigm in innate immunity: friend or foe?. Periodontol 2000 2013, 63:165-197.
63. Koro C., Bielecka E., Dahl-Knudsen A., Enghild J.J., Scavenius C., Brun J.G., et al. Carbamylation of immunoglobulin abrogates activation of the classical complement pathway. Eur J Immunol 2014 Aug 13, [Epub ahead of print].
64. Gomes D.A.S., Pires J.R., Zuza E.P., et al. Myeloperoxidase as inflammatory marker of periodontal disease: experimental study in rats. Immunol Invest 2009, 38:117-122.
65. Nizam N., Gümüş P., Pitkänen J., Tervahartiala T., Sorsa T., Buduneli N. Serum and salivary matrix metalloproteinases, neutrophil elastase, myeloperoxidase in patients with chronic or aggressive periodontitis. Inflammation 2014 May 6, [Epub ahead of print].
66. Ramírez J.H., Parra B., Gutierrez S., Arce R.M., Jaramillo A., Ariza Y., et al. Biomarkers of cardiovascular disease are increased in untreated chronic periodontitis: a case control study. Aust Dent J 2014, 59:29-36.
67. Leppilahti J.M., Hernández-Ríos P.A., Gamonal J.A., Tervahartiala T., Brignardello-Petersen R., Mantyla P., et al. Matrix metalloproteinases and myeloperoxidase in gingival crevicular fluid provide site-specific diagnostic value for chronic periodontitis. J Clin Periodontol 2014, 41:348-356.
68. de Smit M.J., Janssen K.M., Brouwer E., et al. Presence of systemic arthritis autoantibodies in non-RA patients with severe periodontitis. Ann Rheum Dis 2013, 72(Suppl. 3):A814-A815.
69. Golub L.M., Payne J.B., Reinhardt R.A., Nieman G. Can systemic diseases co-induce (not just exacerbate) periodontitis? A hypothetical "two-hit" model. J Dent Res 2006, 85:102-105.
70. Gully N., Bright R., Marino V., et al. Porphyromonas gingivalis peptidylarginine deiminase, a key contributor in the pathogenesis of experimental periodontal disease and experimental arthritis. Plos One 2014, 9:e100838.
71. Maresz K.J., Hellvard A., Sroka A., et al. Porphyromonas gingivalis facilitates the development and progression of destructive arthritis through its unique bacterial peptidylarginine deiminase (PAD). PLoS Pathog 2013, 9:e1003627.